



See the
difference

LED Medical Diagnostics Inc.

(TSXV: LMD) (OTCQX: LEDIF) (Frankfurt Stock Exchange: LME)



Corporate Presentation | October 7, 2015

A preliminary prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of British Columbia, Alberta and Ontario. A copy of the preliminary prospectus, and any amendment, is required to be delivered with this document. The preliminary prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

FORWARD LOOKING STATEMENTS

Certain information contained in this presentation of LED Medical Diagnostics Inc. (the “Company”) constitutes “forward-looking statements” within the meaning of securities laws. Actual events or results could differ materially from expectations and projections. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intent”, “estimate”, “anticipate”, “believe”, “should”, “plans”, or “continue”, or similar expressions suggesting future outcomes or events. Forward-looking statements include, but are not limited to, statements regarding LED’s future plans, strategies, objectives, performance, revenues, growth, profits, operating expenses or LED’s underlying assumptions, LED’s plans to optimize current relationships and VELscope sales channels and LED’s intention to expand its technology beyond dental applications. Persons reading this presentation are cautioned that such statements or information are only predictions, and that LED’s actual future results or performance may be materially different.

Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to: history of losses; the risk of material adverse effects in relation to a warning letter issued by the United States Food and Drug Administration, uncertainty of additional financing; third party product risks; regulatory risk; intellectual property risk; economic conditions; dilution; limited history of operations; operational risk; distributor risks; working capital; potential conflicts of interest; speculative investment; disruptions in production; equipment leases; reliance on key personnel and employees; seasonality; management’s estimates; development of new customers and products risks; stock price volatility risk; sales and marketing risk; competitors and competition risk; changes in barriers to entry for the market; regulatory requirements; reliance on few suppliers; reliance on subcontractors; operating cost and quarterly results fluctuations; fluctuations in exchange rates; fluctuations in interest rates; product liability and medical malpractice claims; access to credit and additional financing; taxation; market acceptance of LED’s products and services; customer and industry analyst perception of LED and its technology vision and future prospects; technological change, new products and standards; risks related to acquisitions and international expansion; reliance on large customers; concentration of sales; international operations and sales; management of growth and expansion; dependence upon key personnel and hiring; LED not adequately protecting its intellectual property; risks related to product defects and product liability; and including, but not limited to, other factors described in the preliminary short form prospectus and the documents incorporated by reference therein. In drawing a conclusion or making a forecast or projection set out in the forward-looking information, LED takes into account the following material factors and assumptions in addition to the above factors: LED’s ability to execute on its business plan; the acceptance of LED’s products and services by its customers; the timing of execution of outstanding or potential customer contracts by LED; the sales opportunities available to LED; LED’s subjective assessment of the likelihood of success of a sales lead or opportunity; LED’s historic ability to generate sales leads or opportunities; and that sales will be completed at or above LED’s estimated margins. This list is not exhaustive of the factors that may affect LED’s forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information.

Except as required by law, the Company disclaims any intention or obligation to update or revise the forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking statements in this document are provided for the limited purpose of enabling potential investors to evaluate an investment in the securities of the Company.

In this presentation, all references to dollars or “\$” are to the lawful currency of Canada and all amounts are in Canadian dollars, unless otherwise indicated.

Securities Offered

No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. The preliminary short form prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. These securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the U.S. except in compliance with exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. The preliminary short form prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of these securities within the U.S. See “Plan of Distribution” in the preliminary short form prospectus.

There is no minimum amount of funds that must be raised under the offering described in the preliminary short form prospectus. This means that LED could complete this offering after raising only a small portion of the offering described in the preliminary short form prospectus.

The Company’s common shares are listed and posted for trading on the TSX Venture Exchange (“TSX-V”) under the symbol “LMD”, on the Frankfurt Stock Exchange under the symbol “LME” and are quoted on the OTCQX under the symbol “LEDIF”. On October 6, 2015, the last trading day on the TSX-V prior to the date of the prospectus, the closing price of the common shares was Cdn\$0.23 on the TSX-V, €\$0.147 on the Frankfurt Stock Exchange and US\$0.1844 on the OTCQX. LED has applied to the TSX-V to list the common shares distributed under the prospectus, the warrant shares and the broker warrant shares. Listing of the common shares, the warrant shares and the broker warrant shares will be subject to LED fulfilling all of the listing requirements of the TSX-V. There is no market for the warrants described in the preliminary short form prospectus and LED does not intend to make application to list such warrants for trading on any exchange. As such, there is no market through which such warrants may be sold and purchasers may not be able to resell warrants purchased under the preliminary short form prospectus. This may affect the pricing of the warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the warrants and the extent of issuer regulation. See “Risk Factors” in the preliminary short form prospectus.

Investing in the units described in the preliminary short form prospectus involves certain risks that should be considered by a prospective purchaser. The risk factors identified under the heading “Risk Factors” in the preliminary short form prospectus and in other documents incorporated therein by reference should be carefully reviewed and evaluated by prospective purchasers before purchasing the units being offered thereunder. Potential investors are advised to consult their own legal counsel and other professional advisors in order to assess income tax, legal and other aspects of the offering described in the preliminary short form prospectus, including the Canadian Federal income tax consequences applicable to a foreign controlled Canadian corporation that acquires common shares described in the preliminary short form prospectus .

WHO WE ARE

LED Medical Diagnostics Inc. provides dentists and oral health care specialists with advanced diagnostic imaging technologies and related software including the industry leading VELscope® Vx tissue fluorescence visualization technology



VELSCOPE® Vx

EXECUTIVE MANAGEMENT

Dr. David Gane | CEO | LED Medical Diagnostics

- Extensive experience in the dental imaging industry in senior executive management positions
- Former Vice President, Dental Imaging, for Carestream Dental LLC (a daughter company of Carestream Health LLC)
- Background as a dental surgeon and a recognized dental imaging expert
- Drive and passion for dental imaging technology, along with experience and distinctive management style



Mr. Lamar Roberts | President | LED Dental

- Responsible for implementing and overseeing the growth programs of some of the largest companies in the medical technology industry
- Developed an industry reputation for guiding companies from early growth stages to becoming industry leaders
- Held several senior executive positions with leaders in the dental industry, including, 360imaging, Carestream Dental and PracticeWorks
- Strong background in leading commercial efforts in technical, medical, and geographically dispersed organizations



OUR COMMITMENT

To build a **high-value dental imaging company** by developing an experienced, peak performing team to **provide** a comprehensive portfolio of **advanced dental imaging technologies** with intense focus on **customer experience**

- **Leadership / Experience**
- **Advanced Technology**
- **Superior Customer Focus**




OUR TECHNOLOGY – VELSCOPE® Vx



The VELscope® technology integrates four concepts:



1. Light
2. Sophisticated filtering
3. Natural tissue fluorophores
4. Human optical and neural physiology.



OUR TECHNOLOGY – VELSCOPE® Vx



- **13,000+ VELscope devices sold** in global market since first-generation
- **VELcaps** (single use disposable)
- Plans to **optimize current relationships with distributors** in North America and to continue to **expand sales in international markets**



LED Partners With London Drugs to Facilitate Oral Cancer Screenings for General Public

LED Dental to Provide VELscopes for London Drugs Oral Cancer Screening Program

VANCOUVER, BC--(Marketwired - April 16, 2015) - LED Dental Inc. ("LED Dental"), a wholly-owned Canadian operating subsidiary of LED Medical Diagnostics Inc. ("LED Medical", "the Company") (TSX VENTURE: LMD) (OTCQX: LEDIF) (FRANKFURT: LME), is partnering with London Drugs to provide its VELscope® Vx Enhanced Oral Assessment Systems ("VELscope® Vx System" or "VELscope® Vx") for a pilot program for oral cancer screenings. The pilot program will be conducted by dental professionals on April 14th, April 15th and April 17th at twelve London Drug pharmacies in the lower mainland of B.C. Canada and has been endorsed by the BC Oral Cancer Prevention Program (BC OCPP) and developed with oral medicine and pathology specialist Dr. Samson Ng of UBC.




OUR PRODUCT STRATEGY

- **Optimize VELscope** product and locate distribution partners in targeted countries
- Execute on **strategic partnerships and accretive acquisitions** to enhance IP portfolio and recurring revenue opportunities
- Identify opportunities to provide a **portfolio of products and services** related to the VELscope and its underlying tissue fluorescence technology including camera systems and laboratory services



LED Medical Inc. Announces Partnership Between LED Dental Ltd. and Ray Co., Ltd., a Subsidiary of Samsung



BURNABY, BRITISH COLUMBIA--(Marketwired - Apr 3, 2014) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD)([LEDIF](#)) ([LME.F](#)) ("LED Medical" or the "Company") announced today that LED Imaging, the new dental imaging division of its wholly-owned operating subsidiary, LED Dental Ltd. ("LED Dental") has partnered with Ray Co., Ltd. ("Ray Co."), a subsidiary of Samsung, to sell, install and provide support for the RAYSCAN α - Expert dental imaging system.


The RAYSCAN α - Expert is a multi-function digital extraoral imaging system with 3D cone beam computed tomography



DENTAL IMAGING MARKET GROWTH

Global market for dental imaging systems was valued at roughly USD\$1.4B in 2013

The chart below was included in the report "Global Markets for Dental Imaging Systems 2014", September 2013, Millennium Research Group, Inc.



Ray Scan – Alpha Expert

According to the report "Global Markets for Dental Imaging Systems 2014", September 2013, Millennium Research Group, Inc., the US CBCT system market will continue to grow reaching a value of USD\$470M by 2022

See the difference

DIGITAL IMAGING PRODUCTS

RAYSCAN α - Expert


- Signed agreement with RAY Co. Ltd. for exclusive distribution to the Canadian market
- Multi-function digital extraoral imaging system



Panoramic



Cephalometric



Cone Beam CT



See the difference

DIGITAL IMAGING PRODUCTS

- LED IC100 / IC200 Intraoral Cameras
- RIOSensor Intraoral Sensors
- LED Imaging Software
 - Integrates with LED's growing portfolio of imaging technologies
 - Designed to be used by various dentists, dental specialists and other oral healthcare practitioners




New Product Offerings

EnvisionTec Inc.

Expanded product line with a distribution agreement with EnvisionTec to include rapid growth 3D printing solutions category for dentists, dental specialists and dental Laboratories across the United States and Canada

3Shape

Expanded product line with a distribution agreement with 3Shape to include the TRIOS line of products, including the new TRIOS 3 digital impression system for the orthodontic market



OUR CHANGING MARKET




- Film-based to digital imaging technology
- High demand for digital dental imaging systems



REVENUE GROWTH

- Revenue for 2013: approximately **US\$2.5M**
- Revenue for 2014: approximately **US\$9.0M**
 - **increase in revenue of 260% from fiscal 2013 to 2014**
- Guidance for fiscal year ending December 31, 2015: **USD\$15.0 - \$16.0M ***
- Q4 sales driven by the seasonality purchasing patterns of equipment in the dental industry



** On January 21, 2015, the Company provided revenue guidance intended solely to give investors an understanding of management's expectations for the full fiscal year in light of recent industry sales trends, seasonality of the business and recognition that much of the sales generated in the dental industry occur in the fourth quarter. The guidance does not take into account, or give effect for, any events that are beyond the Company's reasonable control.*


SUMMARY

- **Experienced and proven management team** - extensive experience in the dental imaging industry in senior executive management positions and industry reputation for guiding companies from early growth stages to becoming industry leaders
- **Significant expansion** in 2014 - expanded its internal sales staff to include outside and inside sales reps to support its expanding market and product line expansion
- **Right space, right time** – The Company believes US consumers desire more modern dental services and US dental practices are generally better able to afford digital imaging solutions, driving growth across all segments of the market
- Value creation through growth, **strategic partnerships and accretive acquisitions**

COMPANY OVERVIEW

Exchanges	(TSXV: LMD) (OTCQX: LEDIF) (Frankfurt Stock Exchange: LME)
Market Cap (10/6/15)	CAN \$23 M (TSXV)
Price (10/6/15)	CAN \$0.23 (TSXV)
Common Shares Outstanding	100,393,519
Fully Diluted Shares Outstanding	135,926,395
Debt	CAN \$1.1 M and US \$0.5 M
FY 2013 Revenues	US\$2.5 M
FY 2014 Revenues	US\$9.0 M
FY 2015 Revenue Guidance	US\$15 M - \$16 M

BOARD OF DIRECTORS




Darryl Yea | Chair of the Board

- Mr. Yea is currently the president of Investco Capital Management Inc., a private Vancouver-based company that invests in a diverse range of businesses and projects and advises on mergers and acquisitions, corporate and strategic issues. Mr. Yea has served on the boards of several public companies.



Rick Pauls | Director

- Mr. Pauls is the President, CEO and Chairman of DiaMedica Inc. Before that, Mr. Pauls was the Managing Director of CentreStone Ventures Inc., an early-stage life sciences venture capital fund. While with CentreStone, Mr. Pauls led the investment in Orasi Medical Inc., winner of the Red Herring Global 100 and Red Herring North America 100 awards; LED Medical Inc., winner of Red Herring Canada 50 award in the Health category; and DiaMedica and Sanomune Inc., both named one of Canada's Top 10TM Life Science Companies.



Roger Tourigny | Director

- Mr. Tourigny is the President of Tourigny Management Ltd., a private consulting company. He has been providing consulting services since 1979 primarily dealing with oil and gas, financial services and real estate. During his 36 years of consulting, Mr. Tourigny has been involved in numerous business ventures including the establishment of a public oil and gas company, managing investment portfolios, purchase and sale of various real estate properties and owning and managing various oil and gas properties.

David Gane and Lamar Roberts both hold director positions on the Board of Directors



LED Medical Diagnostics Inc.

TSX.V: LMD | OTCQX: LEDIF | FSE: LME

580 Hornby Street, Unit 810
Vancouver, British Columbia V6C 2E7
844.952.7327 ▪ www.leddental.com

Investor Relations Contact

Mike Cole

MZ Group - Vice President- North America

Main: 949-444-1341

mike.cole@mzgroup.us

www.mzgroup.us

See the difference